PubRank

Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Clinical Trial ID NCT02220894

PubWeight™ 19.72‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02220894

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015 1.67
2 PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015 1.53
3 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
4 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
5 Pembrolizumab. J Immunother Cancer 2015 0.99
6 Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res 2015 0.99
7 Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol 2016 0.96
8 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
9 Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016 0.89
10 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
11 Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context 2015 0.84
12 Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 2015 0.80
13 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
14 Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Transl Lung Cancer Res 2015 0.78
15 PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016 0.78
16 Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol 2016 0.77
17 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
18 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
19 Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. Nat Rev Clin Oncol 2015 0.76
20 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
21 The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Ann Transl Med 2016 0.75
22 Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. Onco Targets Ther 2016 0.75
Next 100